Ignite Creation Date:
2024-05-05 @ 10:22 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002981
Status:
COMPLETED
Last Update Posted:
2024-06-03
First Post:
1999-11-01
Brief Title:
PET Scan in Treating Patients With Metastatic Prostate Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
11C-Methionine and 2-18F-Fluoro-2-Deoxy-D-Glucose PET Imaging in Patients With Progressive Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE New imaging procedures such as PET scan may improve the ability to detect new or recurrent prostate cancer
Detailed Description:
OBJECTIVES
Measure the pharmacokinetics whole body retention of isotope and biodistribution of C11-methionine and FDG by PET imaging and serial sampling of blood in men with progressive prostate cancer
Explore metabolism of each PET scan by comparing the sensitivity of C11-methionine or FDG by PET scanning in androgen independent prostate cancer metastases with the sensitivity of C11-methionine or FDG in androgen dependent metastases on a site by site basis
Compare C11-methionine and FDG PET scanning to standard of care diagnostic studies which include the Tc 99m bone scan computed tomography and magnetic resonance imaging
Patients fast for 6 hours prior to PET imaging with the exception of liberal water intake which is encouraged A two way catheter is placed in the urinary bladder and continuous isotonic saline irrigation is performed throughout scan acquisition to reduce the interference in imaging lesions in the pelvic lymph nodes and adjacent pelvic bones caused by radiation excreted in urine held in the bladder
Each patient receives C11-methionine intravenously PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures Immediately following the completion of imaging after C11-methionine administration each patient receives FDG intravenously PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures
Measure the pharmacokinetics whole body retention of isotope and biodistribution of C11-methionine and FDG by PET imaging and serial sampling of blood in men with progressive prostate cancer
Explore metabolism of each PET scan by comparing the sensitivity of C11-methionine or FDG by PET scanning in androgen independent prostate cancer metastases with the sensitivity of C11-methionine or FDG in androgen dependent metastases on a site by site basis
Compare C11-methionine and FDG PET scanning to standard of care diagnostic studies which include the Tc 99m bone scan computed tomography and magnetic resonance imaging
Patients fast for 6 hours prior to PET imaging with the exception of liberal water intake which is encouraged A two way catheter is placed in the urinary bladder and continuous isotonic saline irrigation is performed throughout scan acquisition to reduce the interference in imaging lesions in the pelvic lymph nodes and adjacent pelvic bones caused by radiation excreted in urine held in the bladder
Each patient receives C11-methionine intravenously PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures Immediately following the completion of imaging after C11-methionine administration each patient receives FDG intravenously PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G97-1232 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA008748 |
| P30CA008748 | NIH | None | None |
| MSKCC-97007 | None | None | None |